Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.

Privately held: no public share price · China

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 2
IRAK4Small molecule
Atopic Dermatitis
Phase 1
KRAS G12DSmall molecule
Non-Small Cell Lung Cancer

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (3)
January 2028 (1)
LT-002-158Phase 2Atopic Dermatitis (AD)
Est. primary completion 2028-01 · NCT07895615 · CT.gov ↗
What to watch
February 2028 (1)
LT-002-158Phase 1/2Atopic Dermatitis (AD)
Est. primary completion 2028-02-17 · NCT06931990 · CT.gov ↗
What to watch
October 2028 (1)
LT-002-158Phase 1/2Hidradenitis Suppurativa (HS)
Est. primary completion 2028-10-30 · NCT06932003 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.